Cargando…

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata

Systemic infections caused by Candida species are an important cause of morbidity and mortality among immunocompromised and non-immunocompromised patients. In particular, Candida glabrata is an emerging species within the Candida family that causes infections ranging from superficial to life-threate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gamal, Ahmed, Chu, Sherman, McCormick, Thomas S., Borroto-Esoda, Katyna, Angulo, David, Ghannoum, Mahmoud A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cellular and Infection Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006402/ https://www.ncbi.nlm.nih.gov/pubmed/33791244 http://dx.doi.org/10.3389/fcimb.2021.642358

Ejemplares similares

Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections
por: Ghannoum, Mahmoud, et al.
Publicado: (2020)

672. Activity of Ibrexafungerp (Formerly SCY-078) Against Candida auris: In vitro, In Vivo, and Clinical Case Studies of Candidemia
por: Barat, Stephen, et al.
Publicado: (2019)

In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
por: Quindós, Guillermo, et al.
Publicado: (2022)

Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections
por: Angulo, David A., et al.
Publicado: (2022)

Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates
por: Barat, Stephen, et al.
Publicado: (2017)

In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis
por: Sobel, Jack D., et al.
Publicado: (2021)

733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies
por: Scorneaux, Bernard, et al.
Publicado: (2017)

SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis
por: Borroto-Esoda, Katyna, et al.
Publicado: (2017)

Multi-route antifungal administration in the management of urinary Candida glabrata bezoar
por: Viswambaram, Pravin, et al.
Publicado: (2020)

The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation
por: Larkin, Emily, et al.
Publicado: (2017)

Antifungal Activity of Coumarin Against Candida albicans Is Related to Apoptosis
por: Jia, Chang, et al.
Publicado: (2019)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo‐controlled superiority study (VANISH 306)
por: Sobel, R, et al.
Publicado: (2021)

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)
por: Schwebke, Jane R, et al.
Publicado: (2021)

Promising Antifungal Targets Against Candida albicans Based on Ion Homeostasis
por: Li, Yiman, et al.
Publicado: (2018)

Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis
por: Ghannoum, M., et al.
Publicado: (2018)

Investigating Antifungal Susceptibility in Candida Species With MALDI-TOF MS-Based Assays
por: Delavy, Margot, et al.
Publicado: (2019)

Candida glabrata susceptibility to antifungals and phagocytosis is modulated by acetate
por: Mota, Sandra, et al.
Publicado: (2015)

Biguanides enhance antifungal activity against Candida glabrata
por: Xu, Shuying, et al.
Publicado: (2018)

Effect of Antifungal-Treated Host Macrophages on Candida glabrata
por: Li, Hong-Bin, et al.
Publicado: (2021)

Catechin potentiates the antifungal effect of miconazole in Candida glabrata
por: Hervay, Nora Tóth, et al.
Publicado: (2023)

Evaluation of Molecular Epidemiology, Clinical Characteristics, Antifungal Susceptibility Profiles, and Molecular Mechanisms of Antifungal Resistance of Iranian Candida parapsilosis Species Complex Blood Isolates
por: Arastehfar, Amir, et al.
Publicado: (2020)

Antifungal Pipeline
por: McCarty, Todd Patrick, et al.
Publicado: (2021)

Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi
por: An, Lulu, et al.
Publicado: (2023)

Candida auris Identification and Rapid Antifungal Susceptibility Testing Against Echinocandins by MALDI-TOF MS
por: Vatanshenassan, Mansoureh, et al.
Publicado: (2019)

Antifungal and Antibiofilm Efficacy of Paeonol Treatment Against Biofilms Comprising Candida albicans and/or Cryptococcus neoformans
por: Qian, Weidong, et al.
Publicado: (2022)

Insight Into the Properties and Immunoregulatory Effect of Extracellular Vesicles Produced by Candida glabrata, Candida parapsilosis, and Candida tropicalis Biofilms
por: Kulig, Kamila, et al.
Publicado: (2022)

SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration
por: Barat, Stephen, et al.
Publicado: (2017)

Diversity and antifungal susceptibility of Norwegian Candida glabrata clinical isolates
por: Andersen, Kari-Mette, et al.
Publicado: (2016)

Roles of Elm1 in antifungal susceptibility and virulence in Candida glabrata
por: Ito, Yuya, et al.
Publicado: (2020)

Evaluation of antifungal susceptibility in clinical isolates of the Candida glabrata complex
por: Jesus, Filipa, et al.
Publicado: (2021)

Antifungal Resistance in Clinical Isolates of Candida glabrata in Ibero-America
por: Martínez-Herrera, Erick, et al.
Publicado: (2021)

Identification of Off-Patent Compounds That Present Antifungal Activity Against the Emerging Fungal Pathogen Candida auris
por: de Oliveira, Haroldo Cesar, et al.
Publicado: (2019)

Antifungal Peptides as Therapeutic Agents
por: Fernández de Ullivarri, Miguel, et al.
Publicado: (2020)

Potential of Gallium as an Antifungal Agent
por: Bastos, Rafael Wesley, et al.
Publicado: (2019)

How Yeast Antifungal Resistance Gene Analysis Is Essential to Validate Antifungal Susceptibility Testing Systems
por: Pellaton, Nicolas, et al.
Publicado: (2022)

In vitro antifungal susceptibilities of six antifungal drugs against clinical Candida glabrata isolates according to EUCAST
por: Fatahinia, Mahnaz, et al.
Publicado: (2020)

Eucalyptal D Enhances the Antifungal Effect of Fluconazole on Fluconazole-Resistant Candida albicans by Competitively Inhibiting Efflux Pump
por: Xu, Jiali, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1s9udubi827ub41h6kov4q32lc